Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281014 · ClinicalTrials.gov registry record · Phase 4
Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing
A Phase 4 study of Heart Failure, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07281014 is a Phase 4 study of Heart Failure that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07281014, a Phase 4 study of Heart Failure, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to understand the biology related to the potential shortcomings of existing anti-aldosterone therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Spironolactone 25mg
- DRUG Aldosterone
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07281014
The ClinicalTrials.gov registry entry for NCT07281014 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07281014 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07281014 about?
NCT07281014 is a clinical study titled "Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing". The purpose of this research study is to understand the biology related to the potential shortcomings of existing anti-aldosterone therapy.
What is the current status of trial NCT07281014?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-01-27. Estimated completion is 2027-08.
What conditions does trial NCT07281014 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT07281014?
The interventions under investigation include: Placebo (DRUG), Spironolactone 25mg (DRUG), Aldosterone (DRUG).
Who is sponsoring clinical trial NCT07281014?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07281014 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.